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ABSTRACT 
 
Aims: To develop and determine safety of gold nanorods whose aspect ratios can be 
tuned to obtain plasmon peaks between 650 nm and 850 nm, as contrast enhancing 
agents for diagnostic and therapeutic applications. Materials and methods: In this 
study we compared the blood clearance and tissue distribution of cetyl trimethyl 
ammonium bromide (CTAB) capped and poly ethylene glycol (PEG) coated gold 
nanorods after intravenous injection in the tail vein of rats. The gold content in blood 
and various organs was measured quantitatively with inductively coupled plasma 
mass spectrometry (ICP-MS). Results and discussion: The CTAB capped gold 
nanorods were almost immediately (< 15 minutes) cleared from the blood circulation 
whereas the PEGylation of gold nanorods resulted in a prolonged blood circulation 
with a half life time (t1/2) of 19 h and more wide spread tissue distribution. While for 
the CTAB capped gold nanorods the tissue distribution was limited to liver, spleen 
and lung, the PEGylated gold nanorods also distributed to kidney, heart, thymus, brain 
and testes. PEGylation of the gold nanorods resulted in the spleen being the organ 
with the highest exposure whereas for the non-PEGylated CTAB capped gold 
nanorods the liver was the organ with the highest exposure, per gram organ.  
Conclusions: The PEGylation of gold nanorods resulted in a prolongation of the 
blood clearance and the highest organ exposure in the spleen. In view of the time 
frame (up to 48 hours) of the observed presence in blood circulation PEGylated gold 
nanorods can be considered to be promising candidates for therapeutic and diagnostic 
imaging purposes. 
 
 
 
Key words: nanorods, gold, systemic administration, blood clearance, tissue 
distribution.  
INTRODUCTION 
 
Nanotechnology is a rapidly developing technology with the potential to provide our 
society with a wide range of products to be used in various advanced technology 
applications [1]. More specifically there is a general expectation that significant 
progress will be made in various medical applications for diagnostic and therapeutic 
purposes including the potential for specific drug delivery in cancer therapy. 
However, besides the beneficial effects of the developed nanodevices also the 
potential risks should be taken into consideration [2]. For drug delivery 
nanoformulations may consist of the drug itself or at least two components, one being 
the pharmaceutical ingredient and the other one being the nanodevice as drug carrier 
[3-5]. When nanoparticles are used for diagnostic or therapeutic applications one 
should realize that after having fulfilled their function the nanomaterials themselves 
remain and may pose a potential toxicological risk. It is therefore that for drug 
delivery specifically designed biodegradable nanomaterials are preferable over non 
degradable solid nanomaterials which may have the potential for local persistence. 
Also for diagnostic purposes the nanomaterials should be able to be eliminated from 
the body either by biodegradation and metabolism or by elimination via excretion [6].   
 
Kinetic properties are considered to be an important descriptor for potential human 
toxicity and thus for human health risk. In general, the kinetics of a particle consist of 
four processes: absorption, distribution, metabolism, and excretion (ADME). It is 
important to know the amount of the external exposure that is absorbed and results in 
internal exposure. For therapeutic and diagnostic applications mostly a direct systemic 
administration into the blood circulation is used, so the whole dose applied should be 
taken into consideration. Potentially all organs can be reached and are thus considered 
to be at risk for toxic responses. However, to date most particulate materials in the 
systemic circulation, including nanoparicles, are taken up by the so called reticulo 
endothelial system (RES). This results in entrapment of the nanoparticles mainly in 
organs with a high content of mononuclear phagocytes (macrophages) such as liver 
and spleen [7-12]. For diagnostic and therapeutic uses such entrapment in the liver 
should be avoided unless a specific aim is wanted like treatment of liver diseases. One 
approach may be to modify the nanoparticles in order to obtain a more specific organ 
or cellular targeting. The use of carbohydrate binding ligands increased cellular 
binding of  poly(D,L-lactic-co-glycolide)acid (PLGA) nanospheres [13], whereas the 
use of specific antibodies enabled a more specific immunologically directed targeting 
of the nanoparticles [14, 15].  Cellular entrapment in macrophages can be avoided by 
surface modification of the nanoparticles. Coupling of polyethylene glycol (PEG) 
onto the surface of nanoparticles was found to increase their circulation time in the 
blood by inhibiting recognition and phagocytosis by macrophages [16, 17, 18]. Using 
PEGylation of gold nanorods an increase of gold, as measured by inductively coupled 
plasma - mass spectrometry (ICP-MS), in both spleen and tumor tissue was observed 
[17, 19] while the level in the liver was remarkably reduced [17]. In addition, the size 
of nanoparticles can be a significant determinant of particle distribution, as shown for 
spherical gold nanoparticles and gold composite nanodevices [7, 20, 21].  
 
For diagnostic purposes optical imaging is currently under development for detecting, 
diagnosing, staging, and treatment monitoring of disease. Progression of disease is 
usually accompanied by changes in physiology and pathology that are manifested as 
location specific changes in optical properties thereby providing contrast for optical 
imaging to study disease. Imaging techniques use contrast enhancing agents of which 
gold nanoparticles have emerged due to their unusual optical properties and inherent 
biocompatibility [22-24].  
 
Gold metal nanoparticles exhibit narrow and intense absorption and scattering bands 
due to the phenomenon of plasmon resonance, the collective oscillation that the 
conduction electrons experience in an electromagnetic field of the appropriate 
wavelength [25]. The plasmon resonant condition of gold nanoparticles depends upon 
their size, shape, structure (solid or hollow), and upon the refractive index of the 
embedding medium. Spherical gold nanoparticles have a single plasmon resonant 
extinction peak at around 520 nm, which does not shift extensively with changes in 
size and refractive index of the surrounding medium. Due to strong scattering and 
absorption by hemoglobin, at this wavelength, light penetration in tissue is poor and 
gold nanospheres are not useful in contrast enhancement for deep tissue imaging. 
Rod-shaped nanoparticles exhibit two plasmon resonances due to oscillation of the 
conduction electrons along the short axis as well as along the long axis of the 
particles. Thus by tailoring the length and/or width of these particles, their extinction 
peaks may be made to cover the low-energy visible to infrared wavelength regions [1, 
23]. Further, gold-protein chemistry is well developed and several bioconjugation 
protocols are available in the literature, which allows the combination of the targeting 
functionality of antibodies with such gold nanoparticles. The inertness and 
biocompatibility of gold in general hold promise for the use of gold nanoparticles for 
in vivo imaging applications. 
 
The aim of the present study was to determine the influence of PEGylation of gold 
nanorods on the blood clearance and tissue distribution and potential organ 
accumulation in the rat. In this study, we used gold nanorods (AuNR) absorbing in the 
near infrared region (NIR) of the spectrum (peak absorbing wavelength of ~770 nm). 
The PEGylated and non-PEGylated AuNR were intraveneously injected into rats and 
gold content in various organs was determined by ICP-MS. 
 
MATERIALS, ANIMALS, and METHODS 
 
Materials 
 
We used hexadecyltrimethylammonium bromide (CTAB, product Acros 22716V) for 
both growth and seed solutions.  Gold salt (Tetrachloroauric acid HAuCl4.3H2O, 
99.99%) was purchased from Acros Organics (Belgium), sodium borohydride 
(NaBH4, 99%), and ascorbic acid (99%) from Aldrich (The Netherlands), and silver 
nitrate (AgNO3, 99.8%) from Merck (Germany), methoxy PEG thiol (5000 MW) 
from Fluka (The Netherlands). Prior to use, all glassware was cleaned with 
hydrofluoric acid (HF), further with aqua regia (HCl/HNO3 3:1) and rinsed 
thoroughly with Milli Q water. 
 
Synthesis  of  gold nanorods (AuNRs) 
 
In the seed-mediated, surfactant and silver assisted method for the synthesis of AuNR, 
gold nanospheres produced by fast reduction of gold salt are used to seed a growth 
solution in the presence of a weak reductant, a facet-selective capping surfactant and 
silver nitrate (AgNO3) [26]. Specifically, the gold nanospheres are produced by 
reducing gold salt (tetrachloroauric acid) using sodium borohydride in the presence of 
surfactant CTAB. The growth solution comprises tetrachloroauric acid, AgNO3, with 
ascorbic acid as weak reducing agent and CTAB as the capping agent. Reduction of 
gold on the gold seed takes place, but because CTAB assisted by silver passivates 
certain facets of the seed particles, gold deposition occurs preferentially on the 
exposed tips to yield rod-shaped particles.[26, 27]. The AuNR which are synthesized 
by this technique are thus stabilized with a bilayer of CTAB which imparts the 
particle with a net positive charge and helps maintain colloidal stability due to 
electrostatic repulsion.  
We provide here a short description of the steps involved in the protocol, but more 
details may be found in [1, 26].  
 
Preparation of growth solution.: To freshly prepared 0.5 ml of 0.01 M gold salt 
solution, 9.5 ml of 0.1 M CTAB solution was added with thorough mixing to yield a 
dark yellow solution.  To this 60 µl of 0.006M silver nitrate was added. Further 55 µl 
of 0.1 M ascorbic acid was added with stirring. The resultant turned colorless. Ten 
identical growth solutions were prepared to have a final volume of 100 ml suspension 
of nanorods. 
Preparation of gold seed: To freshly prepared 0.25 ml of 0.01 M gold salt solution, 
9.75 ml of 0.1 M CTAB was added with stirring. Ice-cold, freshly prepared 0.01 M 
sodium borohydride solution in a volume of 0.6 ml was added to the mixture all at 
once with stirring for 2 minutes. The resultant seed solution showed a light-brownish 
color and was added within about 5 minutes to the growth solution.  
Growth phase: The seed solution (12 µl) was added to the growth solutions with 
gentle stirring. The resultants were maintained undisturbed at 25 oC for 24 hours after 
which they were centrifuged twice at 10,000 g/20 minutes and the supernatants 
removed. The precipitates were re-dispersed in phosphate buffered saline (PBS). 
 
PEGylation of AuNRs 
 
In vitro cell studies [28-30] have demonstrated that AuNRs carrying CTAB are 
potentially toxic due to the presence of the surfactant. Incubation of the particles with 
mPEG-thiol can cause strong sulfur binding of the polymer’s thiol terminal to the gold 
surface thereby completely or almost completely displacing the CTAB layer. We refer 
to the resulting particles as PEG-AuNR, while the as-prepared particles are designated 
as CTAB-AuNR due to the presence of the surfactant bilayer. 
Details of the PEGylation are described here:  The AuNRs were washed twice at 
10,000g/20 minutes, to rid the dispersion of excess unbound CTAB. The supernatant 
was discarded and to the pellet of  AuRNs, containing approximately 1x1011,  0.5 ml 
of 5mM mPEG-SH was added along with 0.5 ml of PBS, giving a PEG:AuNR ratio of 
approximately 1.5x106:1. The AuNRs were then vortexed for 30 seconds and later 
were kept overnight on stirring. The AuNR were centrifuged once to remove excess 
of PEG thiol and the pellet was dispersed in PBS. No aggregation of the PEG-AuNR 
was observed. The PEGylation of gold nanorods results in stability of the particles in 
PBS solutions in contrast to CTAB coated gold nanorods which tend to flocculate or 
aggregate in PBS with time[ 18].   
 
 
AuNRs characterization . 
 
Electron microscopy of the AuNRs was performed using a Zeiss-1550 high-resolution 
scanning electron microscope (HR-SEM). Particle sizes were estimated using the NI 
Vision module (Labview, National Instruments) on the digital SEM images for which 
approximately 250 particles were considered.   
Optical spectra of nanorods were measured with collimated transmission in a 
Shimadzu PC3101 UV-Vis-NIR spectrophotometer. The nanorods synthesized had 
two plasmon peaks, a transverse plasmon peak at approximately 517 nm and a 
longitudinal plasmon peak at 770 nm. The longitudinal plasmon peak was in the near 
infrared region (NIR) of the spectrum. The concentrations of non-PEGylated and 
PEGylated gold nanorods were determined by the optical spectra. The extinction 
coefficient value of the longitudinal plasmon peak was taken into consideration for 
calculating the number density (particles/ml). The mean length and width of gold 
nanorods were measured. The mass of a single AuNR was calculated by multiplying 
the density of gold with the volume of a rod. The number density was multiplied with 
the mass of gold nanorods to calculate the concentration of Au in µg/ml. 
 
Zeta potential measurements of AuNRs 
 
Zeta potential reflects the charge present on the surface of nanoparticle. The 
measurements were carried out using a Malvern Zetasizer Nano Z(S). One ml 
nanorods were filled in the cuvette (DTS 1060) using a syringe avoiding any air-
bubbles. The CTAB-AuNR showed positive zeta potential due to the presence of the 
positively charged CTAB bilayer on the surfaces of the gold nanorods. The 
PEGylation of gold nanorods caused the displacement of CTAB with PEG and hence 
the surface charge changes to neutral. The zeta potential of the original CTAB capped 
gold nanorods (CTAB-AuNR) was (+ 42 ± 7.2) mV, while for the PEGylated gold 
nanorods (PEG-AuNR) the zeta potential was (+0.4 ± 2.1) mV.  
The results of the characterization of the gold nanorods are presented in Table 1. The 
optical spectra and a HR-SEM image of the gold nanorods are presented in Figure 1.  
 
Animals 
 
Six-week-old male Wistar rats (HsdCpb:WU) were purchased from Harlan Nederland 
BV (Horst, The Netherlands) and allowed to acclimatize for 2 weeks before starting 
the experiment. Animals were bred under specific pathogen-free (SPF) conditions and 
barrier maintained during the entire experiment in Macrolon cages at a room 
temperature of (23 ± 1)°C, a relative humidity of (50 ± 5)% and a 12-hours light/dark 
cycle. Drinking water and conventional feed were provided ad libitum. The 
experiment was approved by an independent Ethical Committee on Animal 
Experimentation and conducted in compliance with all applicable provisions of the 
national laws, i.e. the Experiments on Animal Decree and the Experiments on Animal 
Act. 
 
Experimental design 
 
Rats were divided in 3 groups: CTAB-AuNR (n=6), PEG-AuNR (n=6), and PBS 
vehicle control (n=3). Four days prior to the start of the experiment, a single venous 
blood sample (tail vein; 100 μl) was obtained from the animals in the control group. 
On day 0, rats were intravenously injected (tail vein) with either 1 ml nanogold 
dispersion or vehicle control. The injections were well tolerated and no adverse 
effects were observed during the entire experiment. Starting at day 0 venous blood 
samples were obtained from the treatment-groups at 0.25 (15 minutes), 0.5 (30 
minutes), 1, 2, 4, 8, 24 (day 1), 48 (day 2), 96 (day 4), and 144 (day 6) hours after 
injection. Blood samples from the animals in the control group were collected at day 
“minus” 4 (96 hours before the start of the experiment) and at day 8 (192 hours after 
start of the experiment). At 24 hours (day 1) and  144 hours (day 6) after the injection, 
rats (n=12, 6 per treatment group) and at 192 hours (day 8) the 3 control rats were 
anaesthetized with isoflurane (Isoflu®, AST Pharma, Oudewater, The Netherlands) in 
oxygen and subsequently euthanized by drawing blood from the abdominal aorta. 
Next to blood, liver, spleen, kidneys, lungs, heart, thymus, brain and testes were 
collected. Organs were weighed and homogenized. All samples were stored at -20°C 
for determination of the gold content. After subjecting the sample material to a 
digestion process, the gold content was determined by inductively coupled plasma 
mass spectrometry (ICP-MS).  
 
Sample pre-treatment  and inductively coupled plasma- mass spectrometry (ICP-
MS) 
 
Reagents : All chemicals used for ICP-MS were of analytical grade or of high purity. 
Nitric acid (HNO3) and hydrochloric acid (HCl) were purchased from Merck, 
Darmstadt, Germany. The calibration standard solution of gold (Au), as well as a 
solution of the element rhodium (Rh) used as internal standard, were prepared using 
single element stock solutions with a concentration of 1,000 µg/ml from Inorganic 
Ventures, supplied by Instrument Solutions, Nieuwegein, The Netherlands. Deionised 
water (H2O) with 17.2 MΩcm was produced by a system from Christ, Zoeterwoude, 
The Netherlands.  
Instrumentation: A drying cabinet, from Heraeus, type T6060 (supplied by Thermo, 
Breda, The Netherlands) was used. For the digestion of the sample materials, a Stuart 
block heater SBH200D (supplied by Omnilabo, Breda, The Netherlands) was used. 
The presence of gold was measured with an inductively coupled plasma mass 
spectrometer (ICP-MS, type ELAN DRC Plus, Perkin Elmer, Groningen, The 
Netherlands).  
Accuracy and quality control aspects of the analytical procedure: Next to the control 
of chemical blanks, experiments were included to cover different performance 
characteristics and quality control aspects. However, for gold (nanoparticles) in 
biological materials there is no suitable reference material commercially available. 
The matrix effects were studied by the standard addition experiments and calculation 
of the recovery. These standard addition experiments were carried out by spiking 
blood samples of non treated control rats with the nanoparticles (PEG-AuNR and 
CTAB-AuNR) prior to sample pre-treatment and analysis. For gathering details about 
inhomogeneity in the sample material, four blood samples were analysed as 
independent duplicates (sub-samples A and B).  
Sample preparation: To the homogenized organ samples (0.2 - 0.5 g) 0.5 ml 
concentrated HNO3 was added. The samples were placed in the drying cabinet at 50oC 
for 1 hour to pre-dissolve the sample material. Then, the samples were transferred into 
digestion vials by adding three times 0.5 ml concentrated HCl. For blood the sample 
amount was ~ 0.3 g blood, to which 2 ml aqua regia (concentrated HNO3 and 
concentrated HCl (1:3)) was added. The mixture was digested overnight with a 
maximum temperature of 125oC. Afterwards the mixture was transferred into another 
vial, spiked with the internal standard Rh (final concentration: 100 µg/L) and H2O 
was added to a total volume of 10 ml. The total solution was shortly shaken by hand. 
ICP-MS measurement: The quantification was carried out by external calibration with 
internal standard correction. Stock solutions were diluted with diluted (1:5) aqua regia 
to relevant concentration levels. All measurements of standards and samples were 
carried out with the ICP-MS system. The main instrumental operating conditions were 
as follows: RF power 1450 W and nebulizer gas flow 0.91 L/min Air. The following 
isotopes were measured: 197Au and 103Rh as internal standard. 
 
 
RESULTS 
 
Blood clearance 
 
The blood clearance of the intravenously administered gold nanorods is presented in 
Figures 2 and 3. The results show an almost immediate clearance of the CTAB-AuNR 
gold nanorods from the circulation as at 15 minutes after the administration barely 
detectable levels of gold were measured in the blood (Figure 2). For the PEG-AuNR 
blood gold levels remain detectable until 48 hours after the administration (Figure 2). 
Figure 3 presents a description of the blood clearance in a mathematical model. 
Starting with a bi-exponential model, it immediately appeared that the concentration-
time course could well be described with a mono-exponential model: 
    0( ) exp( )C t C k t    
Fitting this model to the data the values 0C   2100 ( 50) ng/g and k   0.036 
( 0.004) -/h were found. The corresponding half life time in blood 1/ 2 ln(2) /t k  is 
19 hours with a 95% confidence interval of 16 to 25 hours. The starting concentration 
of 2100 ng Au/g blood in rats of 300 grams containing 18 grams of blood (60 g/kg 
body weight) results in a calculated administered dose of 37.8 μg.  
 
Tissue distribution. 
 
The gold concentrations were measured in blood, liver, lungs, spleen, brain, heart, 
thymus, kidneys and testes at day 1 (t=24 hours) and at day 6 (t=144 hours) after 
intravenous administration. In control rats (n=3) the gold levels were at or below the 
detection limit (data not shown).  
The gold content in tissues per gram organ is presented in Table 2. The results show 
that the CTAB-AuNR are mainly found in the liver and spleen, and to a lesser extent 
in the lung. Similar levels are observed both on day 1 and day 6 after administration. 
Expressed per gram organ the highest exposure is observed in the liver, followed by 
spleen and lung. For the PEG-AuNR in most organs at t=24 hours and t= 144 hours 
gold could be detected with the highest levels on day 1 in spleen, blood and liver. At 
day 6 clearly accumulation in all organs was observed with the highest level in the 
spleen followed by the liver (Table 2).  
When we consider the total levels of gold in the whole organ for the PEG-AuNR at 
day 1 the highest levels are in the blood followed by liver and spleen (Table 3). In 
most organs investigated gold could be detected indicating the wide spread 
distribution of the PEG-AuNR in the body with the highest level per whole organ in 
the liver (Table 3). Both at day 1 and day 6 for the CTAB-AuNR the highest levels 
are present in the liver at similar magnitude. In addition also in the lung gold could be 
clearly detected. 
Table 4 and Figure 4 show the total recovery in organs when compared to the 
administered dose for day 1 and day 6. The total recovery varied from approximately 
70 to more than 100%. However, the recovery might be overestimated. Based on the 
calculations for the blood clearance for the PEG-AuNR a starting dose of  37.8 μg was 
calculated. The dose administered according to Table 1 based on optical density 
calculations indicate a concentration per ml and thus dose per animal of 25 μg. ICP-
MS measurement of the PEG-AuNR showed a concentration of 34.5 μg which was 
more in line with the figure calculated from the blood concentrations (data not 
shown).   
DISCUSSION 
 
We investigated the blood clearance and tissue distribution of two types of gold 
nanorods, CTAB capped AuNR and PEGylated AuNR, specifically designed as 
potential probes for light based imaging techniques [1]. The main finding was the 
remarkable contrast in blood clearance between the two types: CTAB-AuNR were 
almost directly removed from the blood circulation, whereas for the PEG-AuNR a 
blood half time value of 19 hours was observed.  
 
It has been demonstrated with several types of nanoparticles [31] including gold 
nanoparticles [32, 33], that when incubated with blood, the particles’ surfaces become 
coated with numerous proteins including immunoglobulins which can enhance 
recognition and uptake by cells of the reticuloendothelial system (RES). We contend 
that in our in vivo case with CTAB-AuNR, there is the immediate formation of a 
serum protein ‘corona’ [34-36] comprising opsonin ligands, which initiates the 
mechanisms of recognition and internalization by components of the RES. This 
causes rapid clearance of the CTAB-AuNR from blood with deposition into organs of 
the RES.  
 
When CTAB-AuNR are incubated with mPEG-thiol, strong sulphur binding to the 
gold surface causes replacement of the CTAB bilayer [30, 37] as seen in the near-
neutral zeta-potential values (Table. 1). The PEG layer also stabilizes the NRs against 
aggregation with a steric hindrance mechanism as seen in the retention of the 
characteristic plasmon peaks after PEGylation (Figure 1). The hydrophilic and neutral 
PEG coating on AuNRs prevents or minimizes adsorption of serum proteins [36, 38-
40], and also prevents the close approach of the underlying AuNR to cell surfaces 
[38]. The effect of the PEG coating is then a reduced interaction of the nanocomposite 
with macrophage cell receptors: PEG-AuNRs thus experience prolonged blood 
persistence.  
 
This result is in general agreement with recent studies using AuNRs [16-18], while 
there are major differences in the studies. Firstly, Niidome et al. [16], Akiyama et al. 
[17], and Von Maltzahn et al.[18] used mice for the experiments. Secondly, while the 
PEG lengths used in the studies was the same, the density of the PEG layer on the 
particles is expected to be different. We used polymer in great excess during 
PEGylation with PEG:AuNR ratios of approximately 1.5x106:1, to ensure a complete 
coverage of the gold surfaces. Von Maltzahn et al. [18] actually measured a value 
around 20,000 per particle, while it appears that Niidome and co-workers [16, 17] 
used low PEG:AuNR ratios. With these differences, the blood circulation half-life is a 
parameter which is difficult to compare across these studies. In any case, while we 
measured 70% of the PEGylated particle dose in the blood 24 hours after injection, 
Niidome et al. [16] found only 8% and Akiyama et al. [17] found between 20% to 
40% at the same time point, while von Maltzahn et al. [18] measured 50% of the 
injected dose after 20 hours with a circulation half-life time of 17 h comparable with 
19 h from this work.  
 
Although for diagnostic use the clearance of imaging contrast agents has to be 
reasonably fast, the very rapid blood clearance as seen for the CTAB-AuNR greatly 
diminishes its potential applications considering as well that these particles have been 
shown to be toxic in in vitro studies [28-30]. In this respect the PEG-AuNR show 
promise as they remain in circulation for some time. The half time of 19 hours allows 
the nanorods to reach all organs in the body thus widening the possible use as imaging 
agent.  
 
In addition to the dramatic differences in blood clearance kinetics between the two 
types of particles, the final organ distribution of the particles was also significantly 
different. CTAB-AuNR were taken up predominantly by the liver, and to a lesser 
extent by the spleen followed by the lungs. When expressed as dose per gram organ 
the highest exposure for CTAB-AuNR was observed in the liver, 1.8 times greater 
than in the spleen on the 6th day. (Table 2). On the other hand, the PEG-coating of the 
PEG-AuNR served to shift the distribution profile more towards the spleen with at 
day 6 a dose per gram organ 6.8 times in excess of that in the liver. This effect on 
tissue distribution and internal organ dose is especially relevant for the potential 
toxicity of the used nanomaterials. 
 
As discussed earlier, the CTAB-AuNRs attract a protein corona due largely to their 
positive charge and and are thus opsonized or tagged for uptake by hepatosplenic 
macrophages in general, but in particular by the Kupffer cells in the liver [34-36]. The 
sequestration of the particles into the liver and spleen is rapid, and occurs within 
minutes. On the other hand PEGylation of nanoparticles causes a reduced uptake by 
the Kupffer cells and a promotion of uptake in splenic macrophages. The precise 
mechanism which directs PEG-AuNR towards clearance by the spleen [41] after a 
long blood residence time is not clear, but this general trend has been observed now 
for a few decades for a myriad of nanoparticle types [36, 38-40].  
 
Besides the liver and spleen other organs with detectable gold levels were kidney, 
lung, heart, and to a lesser extent thymus, brain and testes. In the brain the content 
dropped below the detection level at day 6 after administration. However, we have to 
realise that low levels expressed as mass or as percentage of the injected dose still 
may be a considerable amount of nanoparticles. When we look at the 0.19% of the 
injected dose present in the brain at day 1 after injection, this translates to a number of 
approximately 2x108 PEG-AuNR based on the data presented in Table 1. When local 
accumulation in organs would occur this low fraction of the injected dose still may be 
the cause for a delayed toxic response. The elimination of gold nanoparticles from the 
liver was reported to be rather slow with a reduction in gold liver content  of about 9% 
at six months after administration [42]. The percentage recovery of the injected dose 
was for the PEG-AuNR for other organs than liver and spleen below 2% at day 1 
which decreased further below 1% at day 6, indicating the possible elimination of the 
gold nanorods. In liver and spleen there was a considerable increase in gold content 
when comparing the gold level at day 6 with day 1.   
At autopsy as much blood as possible was collected to maximize removal of residual 
blood from the organs. The amount of gold in residual blood is included in the 
measured tissue concentrations. This should be especially considered for the PEG-
AuNR as these remain in circulation for a prolonged time. Hence, tissue levels could 
have been overestimated. However, an organ with a high-blood content like the spleen 
shows at day 1 a higher gold concentration than blood, suggesting that residual blood 
could have had only a minor effect on the amount of gold measured. On the other 
hand, the concentrations found in the other organs (liver, kidney, lung, heart, thymus, 
brain, and testes) were below the concentration in blood. Therefore, contribution of 
residual blood cannot be ruled out for these organs. For the measurements of the 
CTAB-AuNR and the day 6 measurements blood levels are too low to have an effect 
on the tissue measurements. The day 6 measurements clearly show the difference in 
tissue distribution between the PEG-AuNR and CTAB-AuNR with the PEGylated 
gold nanorods showing a more widespread tissue distribution. The total recovery at 
day 6 was relatively low for the PEG-AuNR in contrast to the CTAB-AuNR (Table 
4). This difference might be explained by possible sequestration of the PEG-AuNR in 
tissues and animal carcass not collected and measured with ICP-MS for their gold 
content. The high recovery for the CTAB-AuNR can be explained by the almost 
immediate disappearance of the CTAB-AuNR from the blood and sequestration in the 
liver. As the liver content remained similar between days 1 and 6 this can explain the 
high recovery levels for CTAB-AuNR. 
 
The distribution of the gold nanorods in blood and tissue was determined by 
measuring the gold content of tissue samples by ICP-MS, a method commonly used 
for the determination of the tissue levels of gold nanoparticles [7, 17, 24, 29] and 
other metal nanoparticles in biological systems [43]. Other methods used for 
following the fate of gold nanoparticles are neutron activation either before use [19] 
so the radionucleide Au197 or Au198 is administered, or afterwards in the tissue 
samples by instrumental neutron activation analysis (INAA) [18]. Although the 
method of neutron activation allows the determination of the gold nanoparticles 
themselves when the activation of the nanogold preparation is done before the 
administration to the animals, it also requires specific infrastructures that are not 
easily available. For INAA the same applies as for ICP-MS that the total gold content 
is determined and not specifically the gold nanoparticles. For ICP-MS measurement 
sample preparation (digestion) is needed with e.g. the possibility of loss of the sample 
due to the used procedure. Determination of the tissue distribution of injected 
materials is also possible with the use of a radioactive label, which, depending on the 
label, can be used with a more limited processing method that may limit loss of test 
sample. For more complex composed nanoparticles there is, however, the possibility 
for losing the label, as was previously demonstrated for technetium labeled carbon 
particles used for studying lung passage of inhaled ultrafine particles [45-47]. As the 
degradation of the gold seems unlikely the determination of the gold content in organs 
by ICP-MS is a good measure for the tissue distribution of gold nanomaterials such as 
gold nanoparticles and nanorods. 
 
CONCLUSIONS 
 We demonstrated that the coating of gold nanorods with PEG had a significant effect 
on both the blood clearance and tissue distribution of the gold nanorods. PEGylation 
of gold nanorods resulted in a prolonged blood circulation with a half life time of  19 
hours and more wide spread tissue distribution.  PEGylation of the gold nanorods 
resulted in the spleen being the organ with the highest exposure whereas for the non-
PEGylated CTAB capped gold nanorods the liver was the organ with the highest 
exposure. In view of the time frame (up to 48 h) of the observed increase in blood 
circulation PEGylated gold nanorods can be considered to be promising candidates for 
diagnostic imaging purposes.  
 
 
EXECUTIVE SUMMARY 
 
 PEGylation of gold nanorods prolongs blood circulation time when compared 
to CTAB capped gold nanorods. 
 The prolonged circulation time allows for the use of PEGylated gold nanorods 
as diagnostic imaging agents. 
 PEGylation of the gold nanorods resulted in the spleen to be the organ with the 
highest exposure in contrast to the liver. 
 The increase of spleen exposure by PEGylated nanoparticles needs further 
investigation in view of possible immunotoxic effects   
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TABLES AND FIGURES 
 
 
Table 1 Characteristics of gold nanorods before/after poly ethylene glycol (PEG) coating 
 
 
Samples    CTAB-AuNR   PEG-AuNR 
     ) 
 
Size given as mean (nm)  55.3 x 18.5   55.3 x 18.5  
 
Aspect ratio    3    3 
 
Number concentration (n/ml)   12 x 1011   9.8 x 1010 
 
Mass concentration (µg/ml)  30.5    25  
 
Zeta potential (mV)   + 42 ± 7.2   + 0.4 ± 2.1 
  
 
  
 
Table 2 Gold content in organs per gram tissue as determined by ICP-MS in organs of rats after intravenous administration of PEGylated (PEG-
AuNR) and non-PEGylated (CTAB-AuNR) gold nanorods. 
 
 
  DAY 1       DAY 6 
 
  PEG-AuNR  CTAB-AuNR   PEG-AuNR  CTAB-AuNR 
 
Liver    320 ± 105  2339 ± 390     978 ± 145  2059 ± 299 
Spleen  3477 ± 153  1643 ± 236   6644 ± 1973  1132 ± 204 
Kidney   183 ± 32      13 ± 1     176 ± 29        5 ± 3 
Lung    264 ± 22    239 ± 102     106 ± 17    172 ± 99  
Heart    192 ± 5        3 ± 1     104 ± 13        4 ± 3 
Thymus     66 ± 19        2 ± 0       66 ± 26        2 ± 0 
Brain      27 ± 3        5 ± 6         2 ± 0        2 ± 1 
Testes      33 ± 10        2 ± 0       23 ± 6        2 ± 0 
Blood  1007 ± 76        3 ± 0         3 ± 1        3 ± 0 
Data are presented as gold concentration in ng per gram tissue. Gold nanorods were administered intravenously at day 0. Number of  animals 
(samples) n=3 for day 1 and n=6 for day 6. Tissue samples were prepared by organ digestion before ICP-MS measurement.   
 
 
   
 
Table 3 Gold content in organs of rats after intravenous administration of PEGylated and CTAB gold nanorods. 
 
 
  DAY 1       DAY 6 
 
  PEG-AuNR  CTAB-AuNR   PEG-AuNR  CTAB-AuNR 
 
Liver    4127 ± 1282  28372 ± 3999   12454 ± 960  26535 ± 3954 
Spleen    2183 ± 261      978 ± 181     4112 ± 959      701 ± 126 
Kidney     362 ± 77        26 ± 3       360 ± 50        10 ± 6 
Lung      350 ± 23      293 ± 113       139 ± 20      215 ± 122  
Heart      182 ± 13          3 ± 1         99 ± 14          4 ± 3 
Thymus       40 ± 17          1 ± 0         37 ± 11          2 ± 1 
Brain        47 ± 6        10 ± 12           4 ± 0          4 ± 2 
Testes        99 ± 33          6 ± 0         75 ± 20          6 ± 1 
Blood  18042 ± 1411        53 ± 2         63 ± 10        59 ± 2 
Data are presented as gold concentration in ng per organ. Gold nanorods were administered intravenously at day 0. Number of  animals 
(samples) n=3 for day 1 and n=6 for day 6. 
 
 
 
 
Table 4 Total recovery of gold content in organs as percentage of administered dose. 
 
  PEG-AuNR  CTAB-AuNR 
Day 1  25.43 µg (101.7%) 29.67 (97.3%) 
 
Day 6  17.28 µg (69.1%) 27.47 µg (90.1%)  
 
At day 0 the gold nanorods were intravenously injected. PEG-AuNR as 25 µg per animal, 
and CTAB-AuNR as 30.5 µg per animal. 
 
 
 
 
 
 
Figure 1 Optical spectroscopy and SEM image of gold nanorods 
 
Left, optical spectra of non-PEGylated (CTAB-AuNR) and PEGylated (PEG-AuNR) gold 
nanorods. Right, HR-SEM image of CTAB-AuNR.  
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Figure 2 Blood clearance of PEGylated (PEG-AuNR) and non-PEGylated (CTAB-AuNR) gold 
nanorods. 
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Figure 3 Fitted mono-exponential model of blood clearance of PEGylated gold nanorods (PEG-
AuNR) 
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Fitted mono-exponential model (straight line) and experimental data (symbols). 
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Figure 4 Recovery of gold as percentage of administered dose. 
 
(A) Gold recovery per organ as percentage of 
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(B) Gold recovery as percentage of administered dose 
at day 6
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